曲唑酮与阿米替林治疗抑郁症的对照观察

为比较曲唑酮与阿米替林治疗抑郁症的疗效和副反应，将符合ＣＣＭＤ—３抑郁症诊断标准的患随机分为两组，分别给予曲唑酮和阿米替林治疗，并于治疗前及治疗后第１、２、４、６周分别用汉密尔顿抑郁量表（ＨＡＭＤ）、临床疗效总评量表（ＣＧＬ－ＳＩ）及副反应量表（ＴＥＳＳ）评定。结果，曲唑酮组显效率６２．５％，总有效率为８７．５％；阿米替林组分别为５７．２％和８６．７％。ＨＡＭＤ评分两组间疗效无显差（Ｐ＞０．０５）。不良反应：曲唑酮表现为镇静，阿米替林为抗胆碱能症状。结论：曲唑酮是一种疗效与阿米替林相当，而副作用较轻的抗抑郁药。     

曲唑酮与阿米替林治疗抑郁症的比较

目的 :比较曲唑酮与阿米替林治疗抑郁症的疗效。　方法 :92例抑郁症患者随机分配至曲唑酮组和阿米替林组。经 1周清洗期后分别以 2药治疗 ,剂量均为 15 0～ 30 0 mg/ d。治疗 4周后以Hamilton抑郁量表 (HAMD)及现行四级标准评定疗效 ,以 Asberg抗抑郁剂副反应量表评定不良反应。　结果 :曲唑酮组显效率为 6 5 .2 % ,总有效率为 86 .9% ,阿米替林组分别为 5 6 .5 %和 82 .6 % ,HAMD总分及各因子分的减分两组间无显著差异 (P>0 .0 5 )。两组的不良反应曲唑酮为镇静 ,阿米替林为抗胆碱能症状 ,对心脏的影响曲唑酮明显较阿米替林为轻。　结论 :曲唑酮是一种强效而安全的抗抑郁药。     

盐酸曲唑酮与阿米替林治疗抑郁症的疗效观察

为探讨盐酸曲唑酮治疗抑郁症的疗效与安全性,以阿米替林为对照进行临床研究,现报告如下.     

曲唑酮与阿米替林治疗焦虑性神经症的对照研究

目的比较曲唑酮与阿米替林治疗焦虑性神经症的疗效和副反应.方法 64例符合CCMD-2-R诊断标准的焦虑性神经症患者,随机分为两组,应用曲唑酮(32例)、阿米替林(32例)治疗六周.采用焦虑自评量表(SAS)、Hamilton焦虑量表(HAMA)和副反应量表(TESS)评定疗效和副反应.结果曲唑酮与阿米替林治疗焦虑性神经症均有疗效,二者疗效相当(P＞0.05).曲唑酮的副反应明显少于阿米替林(P＜0.01).结论曲唑酮是治疗焦虑性神经症的安全、有效药物.     

阿米替林与阿米替林合并逍遥散治疗抑郁症临床对照研究

为了探讨阿米替林和阿米替林合并逍遥散对抑郁症的疗效,我们从1992年1月至1995年4月用国产阿米替林对60例抑郁症病例进行了对照研究。 60例抑郁症均符合中国精神疾病诊断标准—Ⅱ情感性障碍抑郁发作的诊断标准,均系门诊病     

百忧解与阿米替林治疗抑郁症对照研究

选用百忧解和阿米替林治疗抑郁症６０例的对照研究，结果发现：百忧妥抗抑郁作用与阿米替林相当，两种药物疗效均有９０％以上，无显著性差异。从副反应方面观察，百忧解明显较阿米替林少而轻微，且有显著差异，尤以神经系统，心血管系统及抗胆碱能副反应为少见。提示百忧解是一种较理想的新型抗抑郁药。     

舒曲林与阿米替林治疗抑郁症对照研究

目的：观察舍曲林治疗抑郁症的疗效和安全性。方法：口服舍曲林或阿米替林各治疗抑郁症36例,疗程6周,采用汉密尔顿抑郁量表（HAMD）和副反应量表（TESS）在治疗前和治疗后1、2、4、6周末评定药物疗效和副反应。结果：两组疗效无显著差异,HAMD总分及各因子分从疗后2周至6周均较治疗前显著降低,两组间则无显著差异。治疗结束时TESS评分舍曲林组显著低于阿米替林组。结论：舍曲林治疗抑郁症疗效好,副反应小,服用方便、安全,可首选使用。     

米氮平与阿米替林治疗抑郁症对照研究

探讨米氮平治疗抑郁症的疗效和安全性，对此进行对照研究，现报告如下。     

麦普替林与阿米替林治疗老年抑郁症双盲对照研究

用国产麦普替林与阿米替林随机双盲对照治疗２６例老年抑郁症，结果发现二者疗效相近，麦普替林组副反应比阿米替林组少且轻微。看来，麦普替林似较适用于老年抑郁患者。     

舍曲林与阿米替林治疗抑郁症对照研究

目的：观察舍曲林治疗抑郁症的疗效和安全性。方法：口服舍曲林或阿米替林各治疗抑郁症36例,疗程6周,采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)在治疗前和治疗后1、2、4、6周末评定药物疗效和副反应。结果：两组疗效无显著差异,HAMD总分及各因子分从疗后2周至6周均较治疗前显著降低,两组间则无显著差异。治疗结束时TESS评分舍曲林组显著低于阿米替林组。结论：舍曲林治疗抑郁症疗效好,副反应小,服用方便、安全,可首选使用。     

A lasting change in trazodone response after non-convulsive electroshock therapy for medication-resistant senile depression

Abstract A senile patient showed a dramatic recovery from medication-resistant depression after non-convulsive electro-shock therapy (nc-EST), with a lasting change in response to trazodone, which mainly acts as a serotonin re-uptake inhibitor. This result suggests that a change in the serotonin reuptake mechanism may be involved in the effect of nc-EST on depression.     

艾司西酞普兰与文拉法辛治疗抑郁症对照研究

目的：比较艾司西酞普兰与文拉法辛治疗抑郁症的疗效与安全性。方法：采用艾司西酞普兰与文拉法辛对48例抑郁症患者进行为期6周的双盲对照研究,用汉密尔顿抑郁量表（HAMD）、临床疗效总评量表（CGI）在治疗前及治疗1、2、4、6周评定疗效;用治疗中出现的症状量表（TESS）评定不良反应。结果：治疗6周后艾司西酞普兰组与文拉法辛组的有效率分别为87.50%和83.33%,两组差异无显著性。2药起效均较快,不良反应均较轻。结论：艾司西酞普兰与文拉法辛均是安全有效的抗抑郁药。     

Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: Dose-finding study with no concomitant use of hypnotic agent

This was the first dose-finding study of trazodone that was designed to be free of the concomitant use of hypnotics, in which the drug was administered in a single dose for sleep disorders combined with a depressive state. As a result, trazodone at the dosage of 50-100 mg/day improved sleep disorders, particularly at the 100 mg/day dosage. It was confirmed that trazodone improved sleep disorders combined with a depressive state when it was administered in a single dose before bedtime with no concomitant hypnotics.     

西酞普兰与文拉法辛治疗老年期抑郁症对照研究

目的：比较西酞普兰与文拉法辛对老年期抑郁症的疗效及不良反应.方法：将58例符合中国精神障碍分类与诊断标准第3版诊断标准的老年期抑郁症患者随机平分为两组,分别给予西酞普兰与文拉法辛治疗6周.采用汉密尔顿抑郁量表（HAMD）、临床疗效总评量表（CGI）及副反应量表（TESS）评定疗效和不良反应.结果：治疗6周后西酞普兰组和文拉法辛组的有效率分别为89.7%和86.2%,两组差异无显著性.起效均较快、不良反应少而轻微.结论：西酞普兰与文拉法辛都是治疗老年期抑郁症较理想药物.     

Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study

Objective: Trazodone is an effective antidepressant. The present study was designed as a non-interventional open-label, multi-centre, post-marketing study. The aim of the study was to evaluate the therapeutic effectiveness and tolerability of trazodone retard formulation (Trittico^® retard) in everyday clinical practice.

Methods: Two hundred and forty-two patients with depressive disorder from 19 different centres were included in the study. The antidepressant and anxyolitic effects were assessed using Hamilton anxiety rating scale 14 items version, Hamilton depression rating scale 14 items version and Clinical Global Impression Severity scale.

Results: After only two weeks of therapy, a statistically significant improvement in the HAM-D score, was observed. This observation was maintained over the whole study period, up to the day 56.

Conclusions: Our study points toward clinical effectiveness of the prolonged-release formulation of trazodone in the treatment of unselected depressed patients in real-world practice.     

文拉法辛和氯米帕明治疗老年抑郁症对照研究

目的:比较文拉法辛和氯米帕明对老年抑郁症的疗效和不良反应。方法:70例老年抑郁症患者随机分为两组,分别用文拉法辛和氯米帕明治疗,疗程6周。采用汉密尔顿抑郁量表(HAMD)、临床疗效总评量表(CGI)和副反应量表(TESS)评定疗效和不良反应。结果:文拉法辛和氯米帕明治疗老年抑郁症疗效相似,但文拉法辛比氯米帕明见效快,不良反应轻,疗效指数好于氯米帕明(P<0.05)。结论:文拉法辛是一种安全有效、见效快、不良反应轻的治疗老年抑郁症的药物。     

A pilot placebo-controlled study of trazodone and buspirone in alzheimer's disease

The pharmacological management of behavioural symptoms in Alzheimer's disease is limited by the dearth of effective agents in this area. The purpose of this study was to determine whether trazodone or buspirone are helpful in the treatment of behavioural disturbance in AD. Ten patients meeting NINCDS criteria for AD with behavioural complications were administered trazodone (up to 50 mg tid), buspirone (10 mg tid), and placeboin a 12-week double-blind, crossover design. Outcome measures were the Brief Psychiatric Rating Scale (BPRS), the Dementia Mood Assessment Scale (DMAS), and the Buschke Selective Reminding Task. The data were analysed by ANOVA. Compared to placebo, trazodone produced a small but significant reduction in BPRS and DMAS scores (p<0.05), indicating improvement in behaviour but no change in cognitive measures. In contrast, buspirone has no significant effect on either behavioural or cognitive measures compared to placebo. The results of this pilot study suggest a beneficial role for trazodone, but not buspirone, in the treatment of behavioural disturbance in AD. Further studies using a wider range of doses of trazodone in more behaviourally disturbed AD patients should now be initiated in an attempt to replicate and expand on this preliminary finding.     

Gender differences in efficacy and sexual function in long-term trazodone treatment (preliminary results)

Objects. To evaluate the effect of trazodone on depressive or anxiety symptoms and sexual function depending on patient gender. Method. A total of 111 patients (59 men, 52 women) subjected to long-term treatment with trazodone were studied. The effect of the therapy was recorded according to the Clinical Global Impression – Severity of Illness (CGI-S) scale. The incidence of sexual dysfunction was assessed on the Utvalg for Kliniske Undersogelser (UKU) scale. Results. The effect of the therapy was similar in both genders. The incidence of diminished sexual desire was low and comparable in both genders; orgasmic dysfunctions were present only in women at the level of statistical significance. A positive correlation between the severity of the illness and the occurrence of diminished sexual desire and orgasmic dysfunction was found in women but not in men. Conclusion. The occurrence of sexual dysfunctions in trazodone therapy was lower than in population. It seems that trazodone is an effective therapy of depressive and anxiety symptoms in both genders and it is convenient for sexually active patients, because the occurrence of sexual dysfunctions was present the general to a low degree.     

Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients

Alcohol-dependent outpatients with persisting insomnia were treated with either gabapentin or trazodone. Patients were assessed at baseline and after 4-6 weeks on medication using the Sleep Problems Questionnaire (SPQ). Of 55 cases initially treated, 9% dropped out due to morning drowsiness. Of the remaining 50 cases, 34 were treated with gabapentin (mean dose +/- SD = 888 +/- 418 mg) at bedtime and 16 were treated with trazodone (105 +/- 57 mg) at bedtime. Both groups improved significantly on the SPQ but the gabapentin group improved significantly more than the trazodone group. Controlled studies are warranted to replicate these findings.     

曲唑酮联合银杏叶提取物治疗血管性抑郁症的疗效对照分析

目的探讨曲唑酮联合银杏叶提取物治疗血管性抑郁症的疗效与不良反应.方法 73例血管性抑郁症患者随机分为曲唑酮联合银杏叶提取物治疗(治疗组)和常规活血化瘀治疗(对照组),疗程8周.采用汉密尔顿抑郁量表(HAMD)、不良反应量表(TESS)评价临床疗效和不良反应.结果曲唑酮联合银杏叶提取物治疗血管性抑郁症在第2周起效,在第8周治疗结束时总有效率为80.6%;不良反应少而轻.结论曲唑酮联合银杏叶提取物治疗血管性抑郁症安全有效.